Syngene International conducted an investor webinar on December 17, 2025, focusing on its Translation and Clinical Research business and the growing clinical trials market opportunity. The webinar provided detailed insights into the company's Translation and Clinical Research (T&CR) business segment and the broader clinical trials market landscape. It was prompted by investor queries following Syngene International's announcement in Q2 FY26 of securing its first global Phase III clinical trial from a U.S.-based biotech company.

Clinical Trials Market Overview

The global Contract Research and Development Manufacturing Organization (CRDMO) market presents significant growth opportunities, with clinical trials forming a substantial segment. The presentation outlined key market dynamics and growth drivers shaping the industry.

The clinical trials market is experiencing robust growth driven by several factors including increasing R&D pipeline growth at 7.00% CAGR, accelerating outsourcing by big pharma companies, patient diversity recruitment pressures, and the rise of virtual biotech companies with limited infrastructure.

Leadership and Expertise

The webinar was led by Dr. Mrinal Kammili, Head of Translational Clinical Research, who joined Syngene International in January 2025 as part of the Executive Committee. Dr. Kammili brings over 27 years of clinical research experience and previously served as Executive Director, Board Member, and Global Head of Business Development at Lambda Therapeutics.

Market Positioning and Growth Drivers

The Asia-Pacific region is leading growth in the clinical trials market, with India emerging as a key destination. The Indian clinical CRO market is projected to grow at 16.00% CAGR from 2024-28, outpacing the global rate and aligning with APAC's growth trajectory.

Key factors driving India's attractiveness include:

• Large population with high disease burden providing access to diverse subject pools
• Availability of skilled workforce with doubled clinical trial investigators from 2015 to 2022
• Reliable regulatory environment following New Drugs and Clinical Trials Rules (2019)
• Supportive geopolitical dynamics
• Significant cost advantage of 40-60% compared to North America and Europe

Syngene's T&CR Business Capabilities

Syngene International's Translation and Clinical Research business operates as an integrated segment within the company's Research Services division. The T&CR business encompasses comprehensive capabilities across the drug development continuum.

The company has completed over 800 BA/BE studies for submissions in regulated markets and maintains partnerships with 180 sites in India and leading CROs across the U.S., U.K., Jordan, Europe, Australia, Sri Lanka, and New Zealand.

Operating Models and Strategic Focus

Syngene International operates through two primary models in the T&CR space. The 2-way model involves direct client engagement for end-to-end clinical trial solutions with milestone-based revenue over 15-24 months. The 3-way model features shared responsibilities for large-scale multi-region trials with diverse population subsets and longer contract timeframes.

The company's strategic focus centers on the "3S formula" - strengthen, stabilize, and streamline existing functions in the near term, while pursuing forward integration into subsequent phases of clinical trials for the mid to long term. This approach emphasizes supporting more complex and new modalities clinical trials while maintaining seamless integration across bioanalysis, translational science, and clinical development.

Future Outlook

The webinar highlighted Syngene International's positioning to capitalize on the growing clinical trials market through its comprehensive platform spanning discovery to commercialization. The company's integrated approach connects laboratory sciences with clinical services, providing clients with continuity across the drug development value chain and reducing development friction through confident bench-to-bedside transitions.

Syngene International , a prominent player in the Contract Development and Manufacturing Organization (CDMO) sector, has announced significant changes in its senior management team, signaling a strategic shift in its CDMO leadership.

Leadership Transition

The company has disclosed that Alex DelPriore, who served as the Head of Large Molecules CDMO and was a member of the Executive Committee, will be leaving the organization with immediate effect. This departure is described as a mutual decision, allowing DelPriore to pursue other career opportunities.

New Appointment

In a move to strengthen its CDMO operations, Syngene International has appointed Dr. Rohtash Kumar as the new Head of CDMO, overseeing both Small and Large Molecules. Dr. Kumar will also join the company's Executive Committee, assuming his role effective December 1, 2025.

Dr. Rohtash Kumar's Profile

Dr. Kumar brings over two decades of experience to Syngene International. His background includes:

• Expertise in R&D, manufacturing, and executive leadership across global CDMO organizations
• Previous role as the leader of Global Technology and Development at Veranova
• Contributions in advancing branded API molecules to market in collaboration with biotech partners
• Multiple patents and publications
• Ph.D. in Organic Chemistry from the University of Delhi
• M.Sc. in Organic Chemistry and an MBA from Chaudhary Charan Singh University
• Membership in American, Canadian, and Indian Medical Societies

Implications for Syngene International

This leadership change comes at a crucial time for Syngene International. The appointment of Dr. Kumar, with his extensive experience in both small and large molecules, suggests a potential focus on integrating and expanding the company's CDMO capabilities across various molecular types.

The company has stated that further information regarding these changes will be available on their official website at www.syngeneintl.com .

Note: This article is based on the latest available information as of November 18, 2025, and reflects the company's official announcements.